Alexandra Savell

1.5k total citations
15 papers, 240 citations indexed

About

Alexandra Savell is a scholar working on Genetics, Hematology and Immunology. According to data from OpenAlex, Alexandra Savell has authored 15 papers receiving a total of 240 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 7 papers in Hematology and 5 papers in Immunology. Recurrent topics in Alexandra Savell's work include Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (5 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Alexandra Savell is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Multiple Myeloma Research and Treatments (5 papers) and Immunodeficiency and Autoimmune Disorders (4 papers). Alexandra Savell collaborates with scholars based in United States, United Kingdom and Germany. Alexandra Savell's co-authors include Jennifer R. Brown, David C. Fisher, Matthew S. Davids, Karen Francoeur, Caron A. Jacobson, Haesook T. Kim, Jon Arnason, Laura Stampleman, Peter Sportelli and Hari P. Miskin and has published in prestigious journals such as Blood, Clinical Cancer Research and Cancer Medicine.

In The Last Decade

Alexandra Savell

13 papers receiving 239 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexandra Savell United States 7 143 111 98 78 73 15 240
Ethan Strattan United States 6 154 1.1× 113 1.0× 117 1.2× 49 0.6× 60 0.8× 12 314
Rose Mantel United States 8 254 1.8× 193 1.7× 59 0.6× 112 1.4× 98 1.3× 13 327
Karen Francoeur United States 9 176 1.2× 136 1.2× 153 1.6× 128 1.6× 131 1.8× 13 366
Laura Stampleman United States 7 113 0.8× 85 0.8× 94 1.0× 115 1.5× 105 1.4× 17 229
John Hanna United States 4 210 1.5× 139 1.3× 58 0.6× 77 1.0× 54 0.7× 6 262
Grégory Lazarian France 5 176 1.2× 136 1.2× 54 0.6× 34 0.4× 40 0.5× 17 203
Jean Cheung United States 8 109 0.8× 97 0.9× 64 0.7× 52 0.7× 30 0.4× 15 203
Juan Garcia‐Talavera Spain 6 178 1.2× 97 0.9× 67 0.7× 75 1.0× 105 1.4× 9 301
Elsa Maître France 10 199 1.4× 146 1.3× 64 0.7× 80 1.0× 27 0.4× 25 266
Alessia Santi Italy 4 214 1.5× 127 1.1× 72 0.7× 115 1.5× 22 0.3× 8 263

Countries citing papers authored by Alexandra Savell

Since Specialization
Citations

This map shows the geographic impact of Alexandra Savell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexandra Savell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexandra Savell more than expected).

Fields of papers citing papers by Alexandra Savell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexandra Savell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexandra Savell. The network helps show where Alexandra Savell may publish in the future.

Co-authorship network of co-authors of Alexandra Savell

This figure shows the co-authorship network connecting the top 25 collaborators of Alexandra Savell. A scholar is included among the top collaborators of Alexandra Savell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexandra Savell. Alexandra Savell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
2.
Nadeem, Omar, Robert Redd, Alexandra Savell, et al.. (2021). A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. Blood. 138(Supplement 1). 2749–2749. 5 indexed citations
3.
4.
Marinac, Catherine R., Robert Redd, Alexandra Savell, et al.. (2021). A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. Blood. 138(Supplement 1). 1659–1659. 3 indexed citations
5.
Penter, Livius, Yi Zhang, Alexandra Savell, et al.. (2020). Local and Systemic Effects of Immune Checkpoint Blockade on Relapsed Myeloid Malignancies Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood. 136(Supplement 1). 34–35. 1 indexed citations
6.
Crombie, Jennifer L., Svitlana Tyekucheva, Zixu Wang, et al.. (2020). Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome. Blood. 136(Supplement 1). 46–47. 12 indexed citations
7.
Ghobrial, Irene M., Chia‐Jen Liu, Robert Redd, et al.. (2019). A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clinical Cancer Research. 26(2). 344–353. 79 indexed citations
8.
Vartanov, Alexander R., Stacey M. Fernandes, Danielle M. Brander, et al.. (2019). High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR). Blood. 134(Supplement_1). 4291–4291.
9.
Crombie, Jennifer L., Svitlana Tyekucheva, Alexandra Savell, et al.. (2019). A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL. Blood. 134(Supplement_1). 1763–1763. 8 indexed citations
10.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2018). Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. The Lancet Haematology. 6(1). e38–e47. 90 indexed citations
11.
12.
Davids, Matthew S., Haesook T. Kim, Danielle M. Brander, et al.. (2017). A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood. 130. 496–496. 8 indexed citations
13.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2017). Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 130. 4317–4317. 1 indexed citations
14.
Davids, Matthew S., Haesook T. Kim, Alexandra Savell, et al.. (2016). TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. Blood. 128(22). 641–641. 15 indexed citations
15.
Davids, Matthew S., Haesook T. Kim, Danielle M. Brander, et al.. (2016). Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. Blood. 128(22). 3243–3243. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ethan Strattan Breakdown of academic impact, for papers by Rose Mantel Breakdown of academic impact, for papers by Karen Francoeur Breakdown of academic impact, for papers by Laura Stampleman Breakdown of academic impact, for papers by John Hanna Breakdown of academic impact, for papers by Grégory Lazarian Breakdown of academic impact, for papers by Jean Cheung Breakdown of academic impact, for papers by Juan Garcia‐Talavera Breakdown of academic impact, for papers by Elsa Maître Breakdown of academic impact, for papers by Alessia Santi
Rankless by CCL
2026